1 Evaluation of Dual-Activity Opioid
... understanding that tolerance and hyperalgesia caused by opioids can be greatly reduced. This discovery eventually led to the creation of dual ligands with both opioid agonist and NPFF antagonist activity. These dual ligands have been shown to prevent tolerance and opioid-induced hyperalgesia while m ...
... understanding that tolerance and hyperalgesia caused by opioids can be greatly reduced. This discovery eventually led to the creation of dual ligands with both opioid agonist and NPFF antagonist activity. These dual ligands have been shown to prevent tolerance and opioid-induced hyperalgesia while m ...
Ch 4 lec 1
... Distribution of Drugs Within the Body Lipid Solubility – ease with drug molecules are soluble in fat. Heroin more lipid soluble than morphine so gets to brain faster; more intense ”rush” Depot Binding – binding of a drug with various tissues of the body or with proteins in the blood. If drug ...
... Distribution of Drugs Within the Body Lipid Solubility – ease with drug molecules are soluble in fat. Heroin more lipid soluble than morphine so gets to brain faster; more intense ”rush” Depot Binding – binding of a drug with various tissues of the body or with proteins in the blood. If drug ...
Bioisosteres
... means less toxicity To decrease side effects and toxicity To increase or decrease metabolism balance (biodegradable + stable) biodegradable so that we get an effect, but stable and resistant to metabolism at the same time so that it reaches the target #BALANCE Ease of administration (oral instea ...
... means less toxicity To decrease side effects and toxicity To increase or decrease metabolism balance (biodegradable + stable) biodegradable so that we get an effect, but stable and resistant to metabolism at the same time so that it reaches the target #BALANCE Ease of administration (oral instea ...
Pharmacology (translated questions from the Dutch master) 2012 1
... efficiency. The patient must take 200 mg/day of Y. Side effects and pharmacokinetic profiles don’t play a role. Which one do you choose in the treatment of hay fever? b. In the use of paracetamol we must keep next risk factors in mind: gastro-duodenal ulcers, bleeding, liver failure, gout, sedation ...
... efficiency. The patient must take 200 mg/day of Y. Side effects and pharmacokinetic profiles don’t play a role. Which one do you choose in the treatment of hay fever? b. In the use of paracetamol we must keep next risk factors in mind: gastro-duodenal ulcers, bleeding, liver failure, gout, sedation ...
Lecture 2 - H2 receptors and proton pump inhibitor 1
... - increased risk of community-acquired respiratory infections & pneumonia Long term use: Vitamin B12 deficiency increased risk of hip fractures ...
... - increased risk of community-acquired respiratory infections & pneumonia Long term use: Vitamin B12 deficiency increased risk of hip fractures ...
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS
... These drugs inhibit competitively the activity of ACE (also termed kininase II) to prevent formation of the active octapeptide, angiotensin II, from the inactive decapeptide, angiotensin I. This occurs in blood and tissues including kidney, heart, blood vessels, adrenal gland and brain. Angiotensin ...
... These drugs inhibit competitively the activity of ACE (also termed kininase II) to prevent formation of the active octapeptide, angiotensin II, from the inactive decapeptide, angiotensin I. This occurs in blood and tissues including kidney, heart, blood vessels, adrenal gland and brain. Angiotensin ...
